AU2015251207B2 - Novel bicyclic or tricyclic heterocyclic compound - Google Patents
Novel bicyclic or tricyclic heterocyclic compound Download PDFInfo
- Publication number
- AU2015251207B2 AU2015251207B2 AU2015251207A AU2015251207A AU2015251207B2 AU 2015251207 B2 AU2015251207 B2 AU 2015251207B2 AU 2015251207 A AU2015251207 A AU 2015251207A AU 2015251207 A AU2015251207 A AU 2015251207A AU 2015251207 B2 AU2015251207 B2 AU 2015251207B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- group
- alkyl
- compound
- groups selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(CCCC=*CCC12)C1C2N(C)* Chemical compound CC(CCCC=*CCC12)C1C2N(C)* 0.000 description 84
- OGNBQKFJHBIUNP-DSVMPHHWSA-N C=C(/N=C(/C1(CC1)C#N)\N1)S/C(/[C@@H]2CNCCCC2)=N\CC1=O Chemical compound C=C(/N=C(/C1(CC1)C#N)\N1)S/C(/[C@@H]2CNCCCC2)=N\CC1=O OGNBQKFJHBIUNP-DSVMPHHWSA-N 0.000 description 1
- LBEUTHQVAAPAPU-UHFFFAOYSA-N C=C(N1CCCC1)S Chemical compound C=C(N1CCCC1)S LBEUTHQVAAPAPU-UHFFFAOYSA-N 0.000 description 1
- ZRRLTFQLHSFHPU-ZCFIWIBFSA-O C=C([C@@H]1NCCC1)[SH2+] Chemical compound C=C([C@@H]1NCCC1)[SH2+] ZRRLTFQLHSFHPU-ZCFIWIBFSA-O 0.000 description 1
- XVZFZRHKPPGSPR-UHFFFAOYSA-N CC(C(N1)=NC2SC(C)=NC2C1=O)F Chemical compound CC(C(N1)=NC2SC(C)=NC2C1=O)F XVZFZRHKPPGSPR-UHFFFAOYSA-N 0.000 description 1
- FMJIYYZIAKONBI-UHFFFAOYSA-N CC(C)(C(C)=[IH])c1ccccc1 Chemical compound CC(C)(C(C)=[IH])c1ccccc1 FMJIYYZIAKONBI-UHFFFAOYSA-N 0.000 description 1
- WXDDEWYHHHPZLF-UHFFFAOYSA-N CC(C)(C)C(N)=C Chemical compound CC(C)(C)C(N)=C WXDDEWYHHHPZLF-UHFFFAOYSA-N 0.000 description 1
- MQIPYQBUXDJFKP-UHFFFAOYSA-N CC(C)(N)O[IH]C Chemical compound CC(C)(N)O[IH]C MQIPYQBUXDJFKP-UHFFFAOYSA-N 0.000 description 1
- VAALSLGKYWGIHV-WAACFVNBSA-N CC(C)/N=C(/[C@H]1C=CC=CC1)\N(CC(C=C[C@H](C)C(C)=C1)=C1OC)C(C/N=C(/[C@@H](CCC1)N1C(OC/C(/C(C)(C)CC#C)=C/C)=O)\SC)=O Chemical compound CC(C)/N=C(/[C@H]1C=CC=CC1)\N(CC(C=C[C@H](C)C(C)=C1)=C1OC)C(C/N=C(/[C@@H](CCC1)N1C(OC/C(/C(C)(C)CC#C)=C/C)=O)\SC)=O VAALSLGKYWGIHV-WAACFVNBSA-N 0.000 description 1
- HJBZEGGZQKWTAD-OQLLNIDSSA-N CC(C)C(/C(/C)=N/C(C)CC(C(C)=O)N)F Chemical compound CC(C)C(/C(/C)=N/C(C)CC(C(C)=O)N)F HJBZEGGZQKWTAD-OQLLNIDSSA-N 0.000 description 1
- GCEWZJXYHGRWOY-UHFFFAOYSA-N CC(SC1N=C(C)N2)=NC1C2O Chemical compound CC(SC1N=C(C)N2)=NC1C2O GCEWZJXYHGRWOY-UHFFFAOYSA-N 0.000 description 1
- LJWSEPJHQFTILS-TUQDCPSNSA-N CC/C(/C)=C/C(N1N=C([C@@H](CCC2)N2C(Oc2ccccc2)=O)SC1=C)=O Chemical compound CC/C(/C)=C/C(N1N=C([C@@H](CCC2)N2C(Oc2ccccc2)=O)SC1=C)=O LJWSEPJHQFTILS-TUQDCPSNSA-N 0.000 description 1
- UFLFSJVTFSZTKX-UHFFFAOYSA-N CC1(C)OCCNC1 Chemical compound CC1(C)OCCNC1 UFLFSJVTFSZTKX-UHFFFAOYSA-N 0.000 description 1
- XKEBTWMOMFKJNM-CLFYSBASSA-N CCC(C)(C)/C(/C)=C(/C(C)=O)\F Chemical compound CCC(C)(C)/C(/C)=C(/C(C)=O)\F XKEBTWMOMFKJNM-CLFYSBASSA-N 0.000 description 1
- RIBWQMWEKNTXTN-CSKARUKUSA-N CCC(C)=[IH](/C=C(\CC)/ONC)ONC Chemical compound CCC(C)=[IH](/C=C(\CC)/ONC)ONC RIBWQMWEKNTXTN-CSKARUKUSA-N 0.000 description 1
- NQRTWQYVJMRCMM-UHFFFAOYSA-N CCC(C)C=C(C=[IH])C([NH2+]C(C(C)C1=[N]=C(C)C)=[U])=NC1=S Chemical compound CCC(C)C=C(C=[IH])C([NH2+]C(C(C)C1=[N]=C(C)C)=[U])=NC1=S NQRTWQYVJMRCMM-UHFFFAOYSA-N 0.000 description 1
- STDFHTBOPXYKLF-UHFFFAOYSA-N CCC(C)N(C(CC)=N)C(CC(N1)=C(C)SC1S(C)=O)=O Chemical compound CCC(C)N(C(CC)=N)C(CC(N1)=C(C)SC1S(C)=O)=O STDFHTBOPXYKLF-UHFFFAOYSA-N 0.000 description 1
- FEWGEKDWRVQTEG-UHFFFAOYSA-N CCC(C)NSC(N=C(c(cccc1)c1OC)NC(C1)=C)=C1N Chemical compound CCC(C)NSC(N=C(c(cccc1)c1OC)NC(C1)=C)=C1N FEWGEKDWRVQTEG-UHFFFAOYSA-N 0.000 description 1
- QLGCUAWFASWYHU-UHFFFAOYSA-N CCC(C1SC(C)=NC1C(O)=C)=O Chemical compound CCC(C1SC(C)=NC1C(O)=C)=O QLGCUAWFASWYHU-UHFFFAOYSA-N 0.000 description 1
- MNCSWMNHZFHTKD-ZGTOLYCTSA-N CCC(NC1=O)=NC2=C1NC([C@@H](CCC1)N1C(Oc1ccccc1)=O)S2 Chemical compound CCC(NC1=O)=NC2=C1NC([C@@H](CCC1)N1C(Oc1ccccc1)=O)S2 MNCSWMNHZFHTKD-ZGTOLYCTSA-N 0.000 description 1
- OYPHZOUOZORUHR-UHFFFAOYSA-N CCCCCC(c1c(N)[s]c(SC)n1)=C Chemical compound CCCCCC(c1c(N)[s]c(SC)n1)=C OYPHZOUOZORUHR-UHFFFAOYSA-N 0.000 description 1
- UOIWOHLIGKIYFE-UHFFFAOYSA-N CCCCCNC Chemical compound CCCCCNC UOIWOHLIGKIYFE-UHFFFAOYSA-N 0.000 description 1
- LDIRUOCQBVWXKQ-NTMALXAHSA-N CCCCN(C1C(C)=O)/C1=C(/C)\S Chemical compound CCCCN(C1C(C)=O)/C1=C(/C)\S LDIRUOCQBVWXKQ-NTMALXAHSA-N 0.000 description 1
- HYAZORBAPJKGIP-QDTXCPDVSA-N CCCCN/C(/C)=N\C(\C)=C(/C)\N=C(/C)\SC Chemical compound CCCCN/C(/C)=N\C(\C)=C(/C)\N=C(/C)\SC HYAZORBAPJKGIP-QDTXCPDVSA-N 0.000 description 1
- DMJBORLGECCZJB-SSDOTTSWSA-N CC[C@@](C)(C(F)(F)F)C(C)=C Chemical compound CC[C@@](C)(C(F)(F)F)C(C)=C DMJBORLGECCZJB-SSDOTTSWSA-N 0.000 description 1
- ZOEYJNNJVOUCCC-UHFFFAOYSA-N CCc1ccccc1C(NCC1N)=NC1S Chemical compound CCc1ccccc1C(NCC1N)=NC1S ZOEYJNNJVOUCCC-UHFFFAOYSA-N 0.000 description 1
- FPXFNRPZBQAYEI-UHFFFAOYSA-N CN(C(C1CC1)=Nc([s]1)c2nc1/S=[O]/C)C2=O Chemical compound CN(C(C1CC1)=Nc([s]1)c2nc1/S=[O]/C)C2=O FPXFNRPZBQAYEI-UHFFFAOYSA-N 0.000 description 1
- WOBQHMSHBCRDSZ-UHFFFAOYSA-N CN(C=NC(S)=C1N)C1=O Chemical compound CN(C=NC(S)=C1N)C1=O WOBQHMSHBCRDSZ-UHFFFAOYSA-N 0.000 description 1
- FBQAWSUEDPOZFQ-UHFFFAOYSA-N COCC(N(C1CC1)C1=O)=Nc2c1nc(SI)[s]2 Chemical compound COCC(N(C1CC1)C1=O)=Nc2c1nc(SI)[s]2 FBQAWSUEDPOZFQ-UHFFFAOYSA-N 0.000 description 1
- YATPHMHMSJUXCJ-UHFFFAOYSA-N CSc1nc(C(N(C2CCOCC2)C(C(F)(F)F)=N2)=O)c2[s]1 Chemical compound CSc1nc(C(N(C2CCOCC2)C(C(F)(F)F)=N2)=O)c2[s]1 YATPHMHMSJUXCJ-UHFFFAOYSA-N 0.000 description 1
- ZIZCGHAZKJXJPB-LYKKTTPLSA-N C[C@@](CN(C)CC1=CC=CCCC1)(C1)NCC1(C)F Chemical compound C[C@@](CN(C)CC1=CC=CCCC1)(C1)NCC1(C)F ZIZCGHAZKJXJPB-LYKKTTPLSA-N 0.000 description 1
- UTRFLLWBQIMLDS-FWJOYPJLSA-N C[C@H](CC(NC(c1ccccc1)=C)=O)SC(N)N1CCCC1 Chemical compound C[C@H](CC(NC(c1ccccc1)=C)=O)SC(N)N1CCCC1 UTRFLLWBQIMLDS-FWJOYPJLSA-N 0.000 description 1
- HYDLFLCDRWBCHY-SCSAIBSYSA-N C[C@H](CO)N(C(C(F)(F)F)=Nc1c2nc(SC)[s]1)C2=O Chemical compound C[C@H](CO)N(C(C(F)(F)F)=Nc1c2nc(SC)[s]1)C2=O HYDLFLCDRWBCHY-SCSAIBSYSA-N 0.000 description 1
- LNXUAXWPZSNDFV-SYPWQXSBSA-N C[C@H]1OCC1N Chemical compound C[C@H]1OCC1N LNXUAXWPZSNDFV-SYPWQXSBSA-N 0.000 description 1
- YQOPBNDPAOTPNH-UHFFFAOYSA-N Cc(cc1C(NC2=O)=NC(C)=C2N)ccc1F Chemical compound Cc(cc1C(NC2=O)=NC(C)=C2N)ccc1F YQOPBNDPAOTPNH-UHFFFAOYSA-N 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N Cc(cccc1)c1N Chemical compound Cc(cccc1)c1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- GMVZUSYIMMRKSD-UHFFFAOYSA-N O=C(N(CCC1)C1C(SC1=NC2=C3CCCC2)=NN1C3=O)Oc1ccccc1 Chemical compound O=C(N(CCC1)C1C(SC1=NC2=C3CCCC2)=NN1C3=O)Oc1ccccc1 GMVZUSYIMMRKSD-UHFFFAOYSA-N 0.000 description 1
- JIDDDPVQQUHACU-UHFFFAOYSA-N O=CC1NCCC1 Chemical compound O=CC1NCCC1 JIDDDPVQQUHACU-UHFFFAOYSA-N 0.000 description 1
- BTFUWRHXCUZGFB-UHFFFAOYSA-N O=[I]NCC1=CCCC=C1 Chemical compound O=[I]NCC1=CCCC=C1 BTFUWRHXCUZGFB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-089185 | 2014-04-23 | ||
JP2014089185 | 2014-04-23 | ||
PCT/JP2015/062165 WO2015163339A1 (ja) | 2014-04-23 | 2015-04-22 | 新規二環性または三環性複素環化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015251207A1 AU2015251207A1 (en) | 2016-12-08 |
AU2015251207B2 true AU2015251207B2 (en) | 2019-08-22 |
Family
ID=54332502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015251207A Active AU2015251207B2 (en) | 2014-04-23 | 2015-04-22 | Novel bicyclic or tricyclic heterocyclic compound |
Country Status (13)
Country | Link |
---|---|
US (1) | US10065972B2 (zh) |
EP (2) | EP3135674A4 (zh) |
JP (1) | JP6442485B2 (zh) |
KR (1) | KR102458990B1 (zh) |
CN (1) | CN106661017B (zh) |
AU (1) | AU2015251207B2 (zh) |
BR (1) | BR112016024455B1 (zh) |
CA (1) | CA2946702C (zh) |
MX (1) | MX2016013913A (zh) |
PH (1) | PH12016502091A1 (zh) |
RU (1) | RU2702113C2 (zh) |
TW (1) | TWI693227B (zh) |
WO (1) | WO2015163339A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6853782B2 (ja) * | 2015-10-22 | 2021-03-31 | 田辺三菱製薬株式会社 | 新規二環性複素環化合物 |
GB201810092D0 (en) * | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
JP7254246B2 (ja) | 2019-11-25 | 2023-04-07 | アムジエン・インコーポレーテツド | デルタ-5デサチュラーゼ阻害剤としての複素環式化合物及び使用方法 |
TW202330552A (zh) * | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
CN114315760A (zh) * | 2021-12-29 | 2022-04-12 | 内蒙古久日新材料有限公司 | 一种2-氯-1-(4-吗啉苯基)-1-丁酮的制备方法及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012073143A1 (en) * | 2010-12-01 | 2012-06-07 | Pfizer Inc. | Kat ii inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5519055A (en) | 1993-08-06 | 1996-05-21 | University Of Maryland At Baltimore | Substituted kynurenines and process for their preparation |
GB9716101D0 (en) * | 1997-07-30 | 1997-10-01 | Pharmacia & Upjohn Spa | Fused heterocyclic compounds |
JP2010518080A (ja) * | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
CA2763960C (en) * | 2009-06-18 | 2014-07-08 | Pfizer Inc. | Bicyclic and tricyclic compounds as kat ii inhibitors |
AU2011336217B2 (en) * | 2010-12-01 | 2015-10-01 | Pfizer Inc. | KAT II inhibitors |
CA2874400A1 (en) | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Tricyclic compounds as kat ii inhibitors |
-
2015
- 2015-04-22 CA CA2946702A patent/CA2946702C/en active Active
- 2015-04-22 KR KR1020167032460A patent/KR102458990B1/ko active IP Right Grant
- 2015-04-22 RU RU2016145602A patent/RU2702113C2/ru active
- 2015-04-22 MX MX2016013913A patent/MX2016013913A/es unknown
- 2015-04-22 US US14/891,845 patent/US10065972B2/en active Active
- 2015-04-22 AU AU2015251207A patent/AU2015251207B2/en active Active
- 2015-04-22 TW TW104112838A patent/TWI693227B/zh active
- 2015-04-22 CN CN201580021257.8A patent/CN106661017B/zh active Active
- 2015-04-22 EP EP15782852.6A patent/EP3135674A4/en not_active Withdrawn
- 2015-04-22 EP EP20158740.9A patent/EP3683222B1/en active Active
- 2015-04-22 WO PCT/JP2015/062165 patent/WO2015163339A1/ja active Application Filing
- 2015-04-22 JP JP2016514958A patent/JP6442485B2/ja active Active
- 2015-04-22 BR BR112016024455-9A patent/BR112016024455B1/pt active IP Right Grant
-
2016
- 2016-10-20 PH PH12016502091A patent/PH12016502091A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012073143A1 (en) * | 2010-12-01 | 2012-06-07 | Pfizer Inc. | Kat ii inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JPWO2015163339A1 (ja) | 2017-04-20 |
KR20160144025A (ko) | 2016-12-15 |
MX2016013913A (es) | 2016-11-15 |
KR102458990B1 (ko) | 2022-10-25 |
TWI693227B (zh) | 2020-05-11 |
PH12016502091B1 (en) | 2017-01-09 |
RU2016145602A (ru) | 2018-05-23 |
US10065972B2 (en) | 2018-09-04 |
EP3683222A1 (en) | 2020-07-22 |
CA2946702A1 (en) | 2015-10-29 |
EP3135674A4 (en) | 2017-12-20 |
CA2946702C (en) | 2022-06-28 |
RU2702113C2 (ru) | 2019-10-04 |
EP3683222B1 (en) | 2021-10-06 |
BR112016024455B1 (pt) | 2023-02-07 |
PH12016502091A1 (en) | 2017-01-09 |
TW201602115A (zh) | 2016-01-16 |
BR112016024455A2 (pt) | 2017-08-15 |
JP6442485B2 (ja) | 2018-12-19 |
CN106661017A (zh) | 2017-05-10 |
EP3135674A1 (en) | 2017-03-01 |
CN106661017B (zh) | 2019-09-24 |
AU2015251207A1 (en) | 2016-12-08 |
RU2016145602A3 (zh) | 2018-11-14 |
WO2015163339A1 (ja) | 2015-10-29 |
US20160376289A1 (en) | 2016-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019240299B2 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
JP6462795B2 (ja) | LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン | |
JP6665154B2 (ja) | 置換尿素誘導体及びその薬学的使用 | |
AU2015251207B2 (en) | Novel bicyclic or tricyclic heterocyclic compound | |
AU2014375500B2 (en) | Kinase inhibitor and use thereof | |
AU2015292048B2 (en) | Compounds | |
JP6853782B2 (ja) | 新規二環性複素環化合物 | |
JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
EP4329888A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
JP6791717B2 (ja) | 医薬組成物 | |
US20240018115A1 (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease | |
OA17357A (en) | Novel 4-(substituted-amino)-7H-pyrrolo[2,3d]pyrimidines as LRRK2 inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |